Etoricoxib is safe and effective in preventing heterotopic ossification after primary total hip arthroplasty

Heterotopic ossification (HO) is a well-known complication after total hip arthroplasty (THA). The origin and pathogenesis of HO are still unknown. The incidence of HO without sufficient prophylaxis varies from 8 to 90% after THA depending on the individual risk profile [1]. Up to 15% of all HO become symptomatic by causing pain and limited range of motion of the affected joint [2, 3]. In 2000, Eggli et al. [4] studied the effect of HO on the satisfaction rate of patients. They showed that severe HO after THA decreases the satisfaction rate to 30% compared to 90% for patients without HO. Low-dose radiation therapy [5] and non-steroidal anti-inflammatory drugs (NSAID) [1] have proven to effectively reduce the rate of HO after THA. However, the use of NSAIDs shows side effects such as gastrointestinal problems, prolonged bleeding time, and an increase of associated fractures [6]. In several studies up to 37% of patients receiving NSAID had to cease this medication due to undesirable side effects [7]. Selective cyclooxygenase (COX)-II blockers have a lower rate of gastrointestinal bleeding compared to classical NSAIDs and seem to be a reasonable alternative for oral prophylaxis with respect to contraindications like for example cardiovascular disorders [8]. Celecoxib, rofecoxib (withdrawn from the market), and etoricoxib have proven to reduce HO after primary THA [8‐11]. The study of Winkler et al. [12] shows an equal efficiency of etoricoxib (90 mg once daily for nine days postoperative) compared to diclofenac (75 mg twice daily for nine days postoperatively) in preventing HO after primary cementless THA. Up to now, there are only two studies published concerning etoricoxib [11, 12], each with a small sample size (42 respectively 47 patients) and a limited follow-up time of 6 months. In the comment regarding the publication of Brunnekreef et al. [11], Zhang et al. [13] recommended a longer follow-up time of at least 1 year, a larger sample size, and special attention to adverse effects of etoricoxib. Winkler et al. [12] described 12.9% adverse events in the etoricoxib group related to the study medication compared to 9.4% in the diclofenac group. The most frequent adverse events in both groups were nausea, vomiting, dizziness, and diarrhea [12].

Our study describes first the results of a larger group of patients (194) getting etoricoxib to prevent HO after primary THA with a follow-up time of at least one year and a detailed verification of side effects and discontinuation rate due to side effects as demanded by Zhang et al. [13].

As COX-2-blockers are a common therapy to prevent HO after THA, the local ethical committee had no objection to this study. The study was conducted according to the Declaration of Helsinki on biomedical research involving human subjects. As a common method describing HO, we used the classification by Brooker et al. [14]. This classification differs in four grades of HO using radiographs of the hip in two planes. Grade 1 means there are few islands of bone in the soft tissue, and grades 2 and 3 mean bone spurs between pelvis and femur leaving at least 1 cm (grade 2) or less than 1 cm space (grade 3) between bones. Grade 4 describes a bony ankylosis of the hip. Hip function was measured using Harris Hip Score (HHS) [15]. The score rates the categories “pain” (44/100 points), “function” (47/100 points), and “range of motion/deformity” (nine/100 points). For calculation of the category “range of motion/deformity,” we used the simplified method described by Haddad et al. [16].

See Tables 1, 2, 3, and 4 for the results.

In at least two subjects (hip dislocation 4 months postoperatively, traumatic fracture 9 months postoperatively) the complication was unrelated to the PAO prophylaxis with etoricoxib. In the remaining five patients (periprosthetic infections, wound healing disorders, cup dislocation), an influence is possible but unlikely.

No subject showed HOs Brooker grade 3 or 4. HOs were found more frequently in men (15 males, 13 females). There was no significant association between the occurrence of HOs and preoperative diagnosis, BMI (body mass index), and result of HHS.

Our investigation shows that etoricoxib is safe and effective in preventing HOs after total hip replacement. Meta-analyses on randomized clinical trials showed that selective COX-2 Inhibitors and non-selective NSAIDs like diclofenac and indomethacin are equally effective in the prevention of HO after THA [8]. We confirm that a period of 10 days taking etoricoxib is sufficient to reduce the rate of HOs. Therefore, side effects based on extended administration of the drug can be avoided respectively reduced. In comparison with Moed and Maxey [17], we found a higher incidence of HOs for male subjects [17]. As no subject showed HOs Brooker grade 3 o 4 no relevant limitation of joint mobility had to be estimated. Most studies in the literature did not report undesired side effects in detail or the abandonment rate as a result of side effects. Cella et al. [7] reported that 37% of the patients that used indomethacin had to cease medication because of side effects. Jockheck et al. [18] reported stop of medication in 15.5% of their patients getting diclofenac for prophylaxis. Such a high abandonment rate is not tolerable as we know that a perioperative radiation is only effective when performed in a time window of 20 h before and 96 h after surgery (optimal effect 8 h before and 72 h after surgery) [1]. In many cases, the oral prophylaxis is terminated later due to side effects and the patient is then outside of this optimal time window for radiation. Thus, an early terminated oral prophylaxis can often not be replaced by a delayed radiation. Consequently, an oral HO prophylaxis should be safe and as reliable as possible in terms of adherence to therapy. In our study, only 2.1% ceased the treatment because of side effects.

Based on our results and the literature, we can summarize that etoricoxib is a very good alternative for oral HO prophylaxis with a low rate of side effects and high adherence to therapy. To increase the validity of the study, it would be useful to add a study including a control group.